Navigation Links
VirtualScopics to Present at Rodman & Renshaw Annual Global Investment Conference

ROCHESTER, N.Y., Sept. 1, 2011 /PRNewswire/ -- VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative imaging for clinical trials, announced today it has been invited to present at the Rodman & Renshaw Annual Global Investment Conference. The conference will be held at the Waldorf Astoria Hotel in New York City on September 11-13, 2011.

The presentation by VirtualScopics' Chief Business & Financial Officer Molly Henderson is scheduled to begin at 12:05pm, ET, on Tuesday, September 13th.  For more information about the conference or to schedule a one-on-one meeting with VirtualScopics' management, contact your Rodman & Renshaw representative or the conference desk at 212-920-3595.

To access the live or archived webcast of the event, visit the "Investor Relations" section of VirtualScopics' website,

About VirtualScopics, Inc.VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development.  VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images.  In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster.  For more information about VirtualScopics, visit

Forward-Looking Statements The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2010 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contact awards, the risk that they may not get signed.  Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.CONTACTS:Investor Relations:Company Contact:Tim Ryan

Molly HendersonThe Shoreham Group

Chief Business and Financial Officer, Sr. Vice President80 Eighth Ave, Ste 1107

500 Linden OaksNew York, NY 10011

Rochester, New York 14625+1 212 242 7777 Direct

+1 585 

SOURCE VirtualScopics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VirtualScopics Reports 2nd Quarter 2011 Results; Revenues Rise 20%
2. VirtualScopics Schedules Second Quarter 2011 Earnings Announcement
3. VirtualScopics to Present at the 10th Annual Needham Healthcare Conference
4. VirtualScopics to Present at the 13th Annual BIO CEO & Investor Conference
5. VirtualScopics Schedules Fourth Quarter/Full Year 2010 Earnings Announcement
6. VirtualScopics Reports 3rd Quarter 2010 Results; Revenues Increase 28%
7. VirtualScopics Schedules Third Quarter 2010 Earnings Announcement
8. VirtualScopics Revenues Hit Another Quarterly Record
9. VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference
10. VirtualScopics and ABX-CRO Collaborate to Enhance Global Molecular Imaging Offerings
11. VirtualScopics Schedules Second Quarter 2010 Earnings Announcement
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: ... License Application (BLA) with the United States ... ABP 501, a biosimilar candidate to Humira ® ... biosimilar application submitted to the FDA and represents Amgen,s ... Sean E. Harper , M.D., executive vice president ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... ... for mental health and wellness consultation, has collaborated with Women’s Web – ... their reader’s queries on topics on mental and emotional well-being relationship, life ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... where preparing the perfect dish and pleasing the palates of attendees is of ... bringing a dish to a seasonal get-together, give these recipes a try this ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director ... about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for ... and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article published November ... more widely heralded as a breakthrough for performing hernia repairs. The article explains that ... surgery is that it can greatly reduce the pain that a patient might otherwise ...
(Date:11/25/2015)... Raton, Florida (PRWEB) , ... November 25, 2015 ... ... diagnostic testing for physicians and athletic programs, launches new Wimbledon Athletics ... importance of testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under ...
Breaking Medicine News(10 mins):